Afrezza + insulin degludec + Rapid-acting Insulin Analog + Basal Insulin
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Jul 7, 2023 → Jun 24, 2024
NCT ID
NCT05904743About Afrezza + insulin degludec + Rapid-acting Insulin Analog + Basal Insulin
Afrezza + insulin degludec + Rapid-acting Insulin Analog + Basal Insulin is a approved stage product being developed by MannKind Corp for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT05904743. Target conditions include Diabetes Mellitus, Type 1.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05904743 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1